+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic Significance of Plasma CLEC-2 (C-Type Lectin-Like Receptor 2) in Patients With Acute Ischemic Stroke



Prognostic Significance of Plasma CLEC-2 (C-Type Lectin-Like Receptor 2) in Patients With Acute Ischemic Stroke



Stroke 2018: Strokeaha118022563-Strokeaha118022563



Background and Purpose- CLEC-2 (C-type lectin-like receptor 2) is a C-type lectin receptor highly expressed on platelets with the prominent involvement in platelet activation, which was increased in coronary heart disease. Given the role of platelet activation in ischemic stroke and the connections between coronary heart disease and ischemic stroke, CLEC-2 might be a candidate marker of ischemic stroke. Here, we aimed to examine the prognostic significance of CLEC-2 in patients with acute ischemic stroke (AIS). Methods- Three hundred fifty-two patients with AIS within 7 days and 112 healthy controls were prospectively studied. Plasma CLEC-2 (pCLEC-2) and some conventional risk factors of stroke were examined. Stroke progression was defined as any new neurological symptoms/signs or any neurological worsening within 7 days after stroke onset, and poor prognosis was defined as modified Rankin scale scores >2 at 90 days. The association between pCLEC-2 and stroke progression/prognosis was evaluated using regression models. Results- Patients with AIS had a significantly higher level of pCLEC-2 than that of healthy controls ( P<0.05). Patients with AIS with progressive stroke or poor prognosis had a much higher level of pCLEC-2 compared with those with stable stroke or good prognosis (all P<0.05). Increasing pCLEC-2 was significantly associated with an increased risk of stroke progression (odds ratio, 1.97; 95% CI, 1.11-3.50; P=0.021) and poor prognosis (odds ratio, 1.70; 95% CI, 1.17-2.48; P=0.006). Patients with the highest pCLEC-2 level were 7- to 8-fold more likely to have stroke progression compared with the lowest quartile (odds ratio, 7.69; 95% CI, 1.43-41.41). Patients with the highest pCLEC-2 level were also more likely to have poor prognosis at 90 days (odds ratio, 5.58; 95% CI, 1.76-17.68). The optimal cutoff points of pCLEC-2 for predicting stroke progression and poor prognosis were 235.48 and 207.08 pg/mL, respectively. Conclusions- Increased pCLEC-2 was associated with stroke progression and poor prognosis at 90 days significantly, which indicates the prognostic role of pCLEC-2 in AIS. However, it needs to be confirmed in large-scale studies.

(PDF emailed within 0-6 h: $19.90)

Accession: 066034092

Download citation: RISBibTeXText

PMID: 30580704

DOI: 10.1161/STROKEAHA.118.022563


Related references

Plasma CLEC-2 (C-Type Lectin Receptor 2) in Patients With Acute Ischemic Stroke. Stroke 2018: Strokeaha118023696-Strokeaha118023696, 2018

Plasma CLEC-2 as a Predictor of Death and Vascular Events in Patients with Acute Ischemic Stroke. European Journal of Neurology 2019, 2019

Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. Journal of Biological Chemistry 285(32): 24494-24507, 2010

Prognostic value of mannose-binding lectin: 90-day outcome in patients with acute ischemic stroke. Molecular Neurobiology 51(1): 230-239, 2015

Prognostic significance of plasma visfatin levels in patients with ischemic stroke. Peptides 42: 101-104, 2014

Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clinica Chimica Acta; International Journal of Clinical Chemistry 378(1-2): 78-85, 2006

Prognostic significance of major lipids in patients with acute ischemic stroke. Metabolic Brain Disease 32(2): 395-400, 2016

Prognostic significance of smoking in patients with acute ischemic stroke within 3 months of onset. Journal of Stroke and Cerebrovascular Diseases 22(6): 792-798, 2014

The clinical prognostic significance of hs-cTnT elevation in patients with acute ischemic stroke. Bmc Neurology 18(1): 118, 2018

Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischemic stroke. 2013

Neutrophil extracellular traps are increased in patients with acute ischemic stroke: prognostic significance. Thrombosis and Haemostasis 117(10): 1919-1929, 2017

Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 33(4): 1048-1052, 2002

Prognostic significance of ischemia-modified albumin in acute ischemic stroke patients: A preliminary study. Annals of Neurosciences 18(1): 5-7, 2011

Prognostic significance of serum cystatin C in acute ischemic stroke patients according to lipid component levels. Atherosclerosis 274: 146-151, 2018

Microalbuminuria in nondiabetic patients with acute ischemic stroke: prevalence, clinical correlates, and prognostic significance. Cerebrovascular Diseases 14(1): 15-21, 2002